Allergan has announced the acquisition of all the assets of...
Allergan has announced the acquisition of all the assets of RetroSense Therapeutics, a private, clinical-stage biotechnology company specializing in innovative gene therapy approaches to restore vision. RetroSense's lead development program, RST-001, is a novel gene therapy for the potential treatment of retinitis pigmentosa (RP). Under the terms of the agreement, ...
To continue reading this article register now.
Already an Eyewear Intelligence subscriber? Sign in here.
Become a member today for full access from just €7,29 a week!
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.